Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINT: Rapidly Cycling Regimen for mCRPC
NCT02903160Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2017
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Abiraterone Acetate Tablets (I), cabazitaxel ginsenoside liposome injection, carboplatin, enzalutamide and radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Time to Disease Progression at 47.8 months. Started Jan 2017; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)cabazitaxel ginsenoside liposome injectioncarboplatinenzalutamideradium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02903160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903160.